Published :
Tables : 43
Figures : 41
Category : Healthcare
No. of Pages : 210
Report Code : HC-1084
Hemophilia treatment market is forecasted to value over CAGR of over 5% during the forecast period of 2022-2028. Hemophilia is a hereditary genetic disorder where the body’s coagulation control or blood clotting ability is impaired. Essentially, due to lack of sufficient amount of blood-clotting proteins or clotting factors, your blood is unable to clot normally. The inherited hemophilia is generally found in men as it is passed to them by the X chromosome of their mother. Hemophilia occurs in three forms – hemophilia A, hemophilia B and hemophilia C. The most commonly formed is the hemophilia A which is due to lack of factor VIII. Hemophilia B occurs due to lack of factor IX and hemophilia C occurs due to lack of factor XI. A limited presence of these disorders will be a driving force for research and development which will in turn boost the market growth during the forecast period. Along with that, government initiatives that are supporting the market and aggressive campaigning for the same will increase the requirement of diagnostics aids. According to NORD, hemophilia A affects 1 in 5,000 males born in the US. It is the second most common inherited clotting disorder and it is estimated that 75% of global hemophilia patient has no proper access to treatment. Presently, there is no cure for hemophilia A and treatments are majorly concentrated on the management of the disease. It is assumed that 60% of the patient population develops a severe form of hemophilia. They are huge demand for effective management of hemophilia due to highly unmet medical need and it offers monopolistic opportunities for manufacture. Further, supportive regulatory conditions like research incentives & fast approvals boosted the research activities in hemophilia A treatment area. Further, technological advancements led to the integration of gene therapies in the treatment of hemophilia A and created opportunities for innovators. North America market is expected to witness high market share in the global market due to supportive regulatory policies and high awareness. It is followed by the European region and it accounts a significant share in the global market. Asia-Pacific regions are expected to witness a high market growth rate during the forecast period due to increasing awareness and changing healthcare policies. Latin America and Rest of the world market are expected to account a small fraction of market share due to lack of awareness. Hemophilia A Treatment market players include: Spark Therapeutics, Novo Nordisk, Pfizer Inc, Bayer AG, CSL Behring, Baxter, Kedrion SPA, Grifols SA, Octapharma AG, Hospira, Inc. and others. Hemophilia Treatment Market Segmentation: By Product Plasama derived coagulation factor concentrates Factor VIII Factor IX Factor XIII Activated prothrombin complex concentrate Von willebrand factor Recombinant coagulation factor concentrates Factor VIII Factor IX Von willebrand factor Desmopressin Antifibrinolytic agents By Type Hemophilia A Hemophilia B Hemophilia C By Region North America Latin America Europe Asia Pacific Middle East and Africa Competitive Landscape: • Tier 1 players- established companies in the market with a major market share • Tier 2 players • Emerging players which are growing rapidly • New Entrants FutureWise Key Takeaways: • Growth prospects • SWOT analysis • Key trends • Key data-points affecting market growth Objectives of the Study: • To provide with an exhaustive analysis on the global Hemophilia Treatment Market by product, by type, by Region • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions (along with countries)—North America, Europe, Asia Pacific, Latin America, and the Middle East • To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions • Profiling of companies to evaluate their market shares, strategies, financials and core competencies Flexible Delivery Model: • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
Hemophilia is a hereditary genetic disorder where the body’s coagulation control or blood clotting ability is impaired. Essentially, due to lack of sufficient amount of blood-clotting proteins or clotting factors, your blood is unable to clot normally. The inherited hemophilia is generally found in men as it is passed to them by the X chromosome of their mother. Hemophilia occurs in three forms – hemophilia A, hemophilia B and hemophilia C. The most commonly formed is the hemophilia A which is due to lack of factor VIII. Hemophilia B occurs due to lack of factor IX and hemophilia C occurs due to lack of factor XI. A limited presence of these disorders will be a driving force for research and development which will in turn boost the market growth during the forecast period. Along with that, government initiatives that are supporting the market and aggressive campaigning for the same will increase the requirement of diagnostics aids.
According to NORD, hemophilia A affects 1 in 5,000 males born in the US. It is the second most common inherited clotting disorder and it is estimated that 75% of global hemophilia patient has no proper access to treatment. Presently, there is no cure for hemophilia A and treatments are majorly concentrated on the management of the disease. It is assumed that 60% of the patient population develops a severe form of hemophilia. They are huge demand for effective management of hemophilia due to highly unmet medical need and it offers monopolistic opportunities for manufacture. Further, supportive regulatory conditions like research incentives & fast approvals boosted the research activities in hemophilia A treatment area. Further, technological advancements led to the integration of gene therapies in the treatment of hemophilia A and created opportunities for innovators.
North America market is expected to witness high market share in the global market due to supportive regulatory policies and high awareness. It is followed by the European region and it accounts a significant share in the global market. Asia-Pacific regions are expected to witness a high market growth rate during the forecast period due to increasing awareness and changing healthcare policies. Latin America and Rest of the world market are expected to account a small fraction of market share due to lack of awareness.
Hemophilia A Treatment market players include:
Spark Therapeutics, Novo Nordisk, Pfizer Inc, Bayer AG, CSL Behring, Baxter, Kedrion SPA, Grifols SA, Octapharma AG, Hospira, Inc. and others.
Hemophilia Treatment Market Segmentation:
By Product
By Type
By Region
Competitive Landscape: • Tier 1 players- established companies in the market with a major market share • Tier 2 players • Emerging players which are growing rapidly • New Entrants
FutureWise Key Takeaways: • Growth prospects • SWOT analysis • Key trends • Key data-points affecting market growth
Objectives of the Study:
• To provide with an exhaustive analysis on the global Hemophilia Treatment Market by product, by type, by Region • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions (along with countries)—North America, Europe, Asia Pacific, Latin America, and the Middle East • To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions • Profiling of companies to evaluate their market shares, strategies, financials and core competencies
Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders 2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study 3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights 4. Global Hemophilia Treatment Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances 5. Global Hemophilia Treatment Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Hemophilia Treatment Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. Global Hemophilia Treatment Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. Global Hemophilia Treatment Market, By Product Historical Analysis and Forecast 2022-2028 (USD Million) 7.1. Plasama derived coagulation factor concentrates 7.1.1. Factor VIII 7.1.2. Factor IX 7.1.3. Factor XIII 7.1.4. Activated prothrombin complex concentrate 7.1.5. Von willebrand factor 7.2. Recombinant coagulation factor concentrates 7.2.1. Factor VIII 7.2.2. Factor IX 7.2.3. Von willebrand factor 7.3. Desmopressin 7.4. Antifibrinolytic agents 8. Global Hemophilia Treatment Market, By Type Historical Analysis and Forecast 2022-2028 (USD Million) 8.1. Hemophilia A 8.2. Hemophilia B 8.3. Hemophilia C 9. North America Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 9.1. Introduction 9.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 9.2.1. U.S.A 9.2.2. Canada 9.2.3. Mexico 9.3. Market Size (USD Million) Forecast for North America 2022-2028 10. Latin America Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 10.1. Introduction 10.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 10.2.1. Brazil 10.2.2. Venezuela 10.2.3. Argentina 10.2.4. Rest of Latin America 10.3. Market Size (USD Million) Forecast for Latin America 2022-2028 11. Europe Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 11.2.1. Germany 11.2.2. U.K 11.2.3. France 11.2.4. Italy 11.2.5. Spain 11.2.6. Russia 11.2.7. Poland 11.2.8. Rest of Europe 11.3. Market Size (USD Million) Forecast for Europe 2022-2028 12. Asia Pacific Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 12.2.1. Japan 12.2.2. China 12.2.3. India 12.2.4. Australia and New Zealand 12.2.5. ASEAN 12.2.6. Rest of Asia Pacific 12.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028 13. Middle East and Africa Market Analysis 2015–2020 and Forecast 2022–2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2015-2020 13.2.1. GCC 13.2.2. Israel 13.2.3. South Africa 13.2.4. Rest of MEA 13.3. Market Size (USD Million) Forecast for MEA 2022-2028 14. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Connected Devices and Disease Indication Portfolio, Financial Layouts) 14.1. Spark Therapeutics 14.1.1. Company Overview 14.1.2. Product Portfolio 14.1.3. SWOT Analysis 14.1.4. Financial Overview 14.1.5. Strategic Overview 14.2. Novo Nordisk 14.2.1. Company Overview 14.2.2. Product Portfolio 14.2.3. SWOT Analysis 14.2.4. Financial Overview 14.2.5. Strategic Overview 14.3. Pfizer Inc 14.3.1. Company Overview 14.3.2. Product Portfolio 14.3.3. SWOT Analysis 14.3.4. Financial Overview 14.3.5. Strategic Overview 14.4. Bayer AG 14.4.1. Company Overview 14.4.2. Product Portfolio 14.4.3. SWOT Analysis 14.4.4. Financial Overview 14.4.5. Strategic Overview 14.5. CSL Behring 14.5.1. Company Overview 14.5.2. Product Portfolio 14.5.3. SWOT Analysis 14.5.4. Financial Overview 14.5.5. Strategic Overview 14.6. Baxter 14.6.1. Company Overview 14.6.2. Product Portfolio 14.6.3. SWOT Analysis 14.6.4. Financial Overview 14.6.5. Strategic Overview 14.7. Kedrion SPA 14.7.1. Company Overview 14.7.2. Product Portfolio 14.7.3. SWOT Analysis 14.7.4. Financial Overview 14.7.5. Strategic Overview 14.8. Grifols SA 14.8.1. Company Overview 14.8.2. Product Portfolio 14.8.3. SWOT Analysis 14.8.4. Financial Overview 14.8.5. Strategic Overview 14.9. Octapharma AG 14.9.1. Company Overview 14.9.2. Product Portfolio 14.9.3. SWOT Analysis 14.9.4. Financial Overview 14.9.5. Strategic Overview 14.10. Hospira, Inc. 14.10.1. Company Overview 14.10.2. Product Portfolio 14.10.3. SWOT Analysis 14.10.4. Financial Overview 14.10.5. Strategic Overview 15. Pre and Post COVID-19 Impact 15.1. Positive influence on the healthcare industry 15.2. The financial disruption of the manufacturing sector 15.3. Impact of COVID-19 on emerging companies 15.4. Significant mandates in the healthcare regulations initiated by administrations 15.5. The overall economic slowdown of the developing and developed nations 16. FutureWise SME Key Takeaway Points for Client
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics